Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer

A Treatment Protocol to Monitor the Safety of a 200 mg Daily Dose of Bicalutamide (Casodex) in Patients With Advanced Prostate Cancer

This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as physician feels that he is benefiting from this form of therapy.

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the prostate gland
• Patients with advanced prostate cancer
• Adult male over the age of 18 years old
• Normal liver function (AST < 2 x Upper Limit Normal)

Exclusion Criteria:

• ECOG performance status of 4.
• Previous history or presence of another malignancy other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last 5 years.